Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

- PMLiVE

GSK and AZ drugs impress in lupus trials

Raises hope for better treatment for debilitating disease

EU flag

EMA review clears GSK and Sanofi Pasteur MSD HPV vaccines

Concludes Cervarix andGardasil don’t cause CRPS or POTS

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

AZ boosts cardio-renal portfolio with $2.7bn ZS Pharma buy

Acquires rights to potential best-in-class treatment for hyperkalaemia

- PMLiVE

Boehringer takes third-generation NSCLC drug into pivotal trials

Startsphase II study of BI 1482694 in patients who test positive for T790M mutation

- PMLiVE

AstraZeneca backs heart website

Works with charity HEART UK on How Young My Heart

- PMLiVE

Consultation begins on new patient access scheme

EMA hopes PRIME will improve development of prioritymedicines and ease access concerns

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

- PMLiVE

AZ moves a step closer to gout drug approval in US

Final verdict to be delivered in end of December

Eli Lilly HQ

Lilly and AZ forge closer immuno-oncology bond

Look to boost their presence in a market predicted to be worth $30bn in 10 years

- PMLiVE

FDA rejects AZ’s diabetes combination

Wants to see more trial data on saxagliptin / dapagliflozin

- PMLiVE

AZ halts durvalumab combination trials on safety grounds

Saysmove is a precautionary step after respiratory disease reports

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links